Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine(R), the reference product, in patients with advanced cancer potentially sensitive to vinorelbine. Equivalence was demonstrated by a statistical comparison of both the areas under the curve (AUC) and maximum plasma concentrations (Cmax). The Company anticipates safety and full clinical results will be available during the first quarter of 2008. Results from this study will be submitted for presentation at an appropriate medical conference.

"We're very pleased with these results, which we believe will provide sufficient clinical data to support a Section 505(b)(2) New Drug Application," said Evan M. Levine, chief executive officer of ADVENTRX. "We have a meeting scheduled with the FDA in December to discuss our commercial manufacturing plans. After we receive the FDA's written comments, we intend to provide an update regarding our NDA timeline for ANX-530."

ANX-530 is a novel emulsion formulation of vinorelbine. Vinorelbine, marketed under the brand name Navelbine(R), also available as generic vinorelbine, is an anti-cancer agent approved to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million.

The bioequivalence study of ANX-530 was a crossover comparison of ANX-530 and Navelbine with a primary objective of demonstrating the pharmacokinetic equivalence of ANX-530
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...BRIDGEWATER, N.J., May 16 /- Data fro...wer mean baseline hemoglobin (Hb) levels,and the r... effect of,restrictions on reimbursement for eryth...tients on the nation,s blood supply, will be prese...(ASCO) Annual Meeting later this,month. The meetin...
(Date:5/16/2008)...RARITAN, N.J., May 16 /- Veridex, LLC...Laboratory Corporation of America Holdings,(LabCor...on test for,prostate cancer. The new assay uses th...rostate cancer, detecting the methylation of the g...hat occurs primarily in,cancer. Veridex is develop...
(Date:5/15/2008)...BASEL, Switzerland, May 15 /- Patient...ld,s most common cancers, can expect,further treat...rceptin(R),(trastuzumab) following new data that i...Clinical Oncology (ASCO) annual meeting in Chicago...will attend the meeting which,is the premier event...
(Date:5/15/2008)...MELBOURNE, Australia, May 15 /PRNewswire-FirstCall...at the abstract for its upcoming oral,presentation...can Society,of Clinical Oncology (ASCO) will be ac.../www.asco.org ) from 9pm on Thursday 15 May (US ED...luation of CYT997, a novel,cytotoxic and vascular ...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6ReBuilder Medical Technologies Inc Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006 Including Record Daily Sales in September 20 2735 1ReBuilder Medical Technologies Inc Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006 Including Record Daily Sales in September 20 2735 2ReBuilder Medical Technologies Inc Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006 Including Record Daily Sales in September 20 2735 3Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap 28PRODUCT 29 RED 2731 1Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap 28PRODUCT 29 RED 2731 2Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap 28PRODUCT 29 RED 2731 3Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap 28PRODUCT 29 RED 2731 4Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 1016 1Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 1016 2Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences 1016 3Halogen Software Wins Top Human Resource Product Award 1012 1Halogen Software Wins Top Human Resource Product Award 1012 2Halogen Software Wins Top Human Resource Product Award 1012 3
...sumers today have to decide between analog and dig...adiology centers have to choose between analog and...y gaining ground in imaging centers around the cou...g Administration (FDA) had cleared four digital ma...0D Full-Field Digital Mammography systems, approve...
...patient glucose levels and determining the respons...abetic clients. The benefit of doing so in improve... been clearly established by clinical trials condu...g by patients of glucose levels, and the data prov...istory of brittle diabetes, hypoglycemic unawarene...
Other Medicine Technology:Digital vs. Analog Mammography 2Digital vs. Analog Mammography 3Digital vs. Analog Mammography 4Monitoring Patient Glucose Levels: New Advances in software make it easier 2Monitoring Patient Glucose Levels: New Advances in software make it easier 3Monitoring Patient Glucose Levels: New Advances in software make it easier 4Monitoring Patient Glucose Levels: New Advances in software make it easier 5
(Date:5/16/2008)...ng presented at the American Society of Clinical O...hange treatment practice in about 25 percent of pa...osed changes to the way colorectal cancers will be...er Institute (NCI) SEER population-based statistic...cal trial data, shows that outcomes of patients wi...
(Date:5/16/2008)...ic disease sufferers gain benefit from calcitriol,...Day News) -- Taking activated vitamin D may cut th... chronic kidney disease by about one quarter, a ne... more than 1,400 patients, those being treated wit... had their overall risk of death lowered by 26 per...
(Date:5/16/2008)...located just beneath the lining of the uterus (sub...l cavity after uterine artery embolization (UAE) b...ng to a new study. , The study included 49 pati...ation before and after UAE. The study found that 3... to the endometrial cavity after UAE, said Sachit ...
(Date:5/16/2008)... Vital Services for Frail Seniors and People With,...-USNewswire/ -- Thousands of,homecare workers acro...egger,s proposed cuts to hours of service, wages a...s most vulnerable workers and the,people they serv...vital,services for seniors and people with disabil...
Breaking Medicine News(10 mins):Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2
... confirmed the death of a Madison County resident ... in 2007 and it seems to be much earlier than the... due to the virus. Four Mississippians have contr...other state has had a case, according to the Healt...
...ve birth to twins at a hospital in London, where s...day, June 9. The 47-year-old and her husband of ...twins, that were due to arrive only next month. P...ival of twins, Chadha also said that her family ha...
... intake of calcium and vitamin D could reduce the ... The four-year clinical trial included more than o...ee supplement groups: calcium) plus vitamin D, cal...rs found that the risk of developing cancer was 60...
...ure Organization (FAO) has warned that diverting f...s would damage biodiversity and lead to a serious ...ve to cope with a nine percent rise on food import... most, will pay an extra 10 percent", the FAO repo...
Other Medicine News:Health News:First Case of West Nile Virus Death in Madison County 2Health News:High Intake of Milk may Reduce Cancer Risks by 60 Percent 2
A fixed pipette is ideal for repeated pipetting of a single volume. Fixed volume FInnpipettes offer the same features and advantages as other Finnpipette Digital pipettes: New, streamlined design, S
... Xpect family, Xpect C. difficile Toxin A/B, detec...e-to-perform test requires no sample preparation, ... Remel Xpect family of rapid diagnostic test kits ...sts that combine exceptional performance with ease...
Inquire
Inquire
Medicine Products: